ストックスクリーナーアプリを入手
0.2825
11.92%
0.03
Cosmos Health Inc (COSM) 最新ニュース
Cosmos Health Releases 2026–2029 Guidance: Targeting $200M Revenue, $71M Gross Profit, and $44M Adjusted EBITDA by 2029 — Building an Innovative, High-Margin Healthcare Platform with Strong Cash G - StreetInsider
Cosmos Health (COSM) Q1 2026: Revenue $17.93M Misses $21.67M Est - GuruFocus
Cosmos Health (NASDAQ: COSM) seeks shareholder votes on equity plan, Series B preferred - Stock Titan
Cosmos Health Q1 2026 Results: Record $17.9M Revenue, Liabilities Down, U.S. Expansion Underway - Minichart
Cosmos Health reports Q1 revenue up 31% to $17.9M; liabilities down $4.5M - TradingView
Cosmos Health (COSM) Q1 revenue up 31% as net loss widens - Stock Titan
Cosmos Health Reports Strong Q1 Results with Record Revenue - GuruFocus
Cosmos Health (COSM) Reports Strong Q1 2026 Revenue Growth - GuruFocus
Cosmos Health’s Series B warrants expire unexercised By Investing.com - Investing.com Nigeria
Cosmos Health’s Series B warrants expire unexercised - Investing.com
Cosmos Health Announces Expiration of 4,874,126 Series B Warrants Unexercised; ~38% of Total Outstanding Warrants - ACCESS Newswire
4.87M Cosmos Health warrants expire with no new shares issued - Stock Titan
Cosmos Health reports Q1 revenue of $17.9M, up 31% year-over-year By Investing.com - Investing.com South Africa
Cosmos Health reports Q1 revenue of $17.9M, up 31% year-over-year - Investing.com
Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway - ACCESS Newswire
BRIEF-Cosmos Health Q1 Revenue USD 17.9 Million - TradingView
Cosmos Health trims $4.5M debt, eyes U.S. nutraceuticals push after record Q1 - Stock Titan
COSM Shows Rapid Revenue Rise - Yahoo Finance
Cosmos Health Inc. 1Q 2026: Revenue $17.93M, EPS ($0.06) — 10-Q Summary - TradingView
Cosmos Health (NASDAQ: COSM) posts Q1 loss and issues going‑concern warning - Stock Titan
Cosmos Health, through its Subsidiary Cana Laboratories, Enters into an Advisory Agreement with the European Investment Bank (EIB) for the Financing of its €50M R&D Program; EIB Financing Represents up to 50%, or €25M, under the EIB's Venture Debt P - ACCESS Newswire
Cosmos Health Company Profile & Introduction - Moomoo
COSM Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Cosmos Health Inc stock (US22143K1016): volatility after reverse split and uplisting plans draw inve - AD HOC NEWS
Cosmos Health Inc.Common Stock (NQ: COSM - FinancialContent
[NT 10-Q] Cosmos Health Inc. SEC Filing - Stock Titan
Cosmos Health (COSM) Engages European Investment Bank for R&D Fi - GuruFocus
Cosmos Health stock (US22143K1016): Pursues €25M EIB financing for R&D - AD HOC NEWS
Cosmos Health pursues €25M EIB financing for R&D program By Investing.com - Investing.com South Africa
Cosmos Health pursues €25M EIB financing for R&D program - Investing.com
Cosmos Health regains compliance with Nasdaq’s listing rule - MSN
Cosmos Health (COSM) Withdraws Registration Statement for Public Offering - GuruFocus
TradingKey - TradingKey
Cosmos Health stock (US22143K1016): Fort18 launch targets $3.2M revenue boost - AD HOC NEWS
Cosmos Health withdraws SEC registration statement - Investing.com UK
Cosmos Health withdraws SEC registration statement By Investing.com - Investing.com South Africa
Cosmos Health Announces Withdrawal of Registration Statement on Form S-1 - ACCESS Newswire
Cosmos Health scraps public offering, pulls SEC registration - Stock Titan
Cosmos Health Projects Over $3.2 Million in Incremental Annual Revenue from Fort18 in the United States Within 12-18 Months - Digital Journal
[RW] Cosmos Health Inc. SEC Filing - Stock Titan
Men's stamina supplement Fort18 targets $3.2M U.S. sales - Stock Titan
Cosmos Health Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
COSM introduces new product for sexual health - MSN
Cosmos Health Receives Updated Zacks Research Report: 2026 Revenue Forecast Raised to $103.2 Million, EPS Outlook Upgraded to Positive Territory, and $4.50 Valuation Reaffirmed - ACCESS Newswire
Cosmos Health(COSM) Stock Options Chain | Quotes & News - Moomoo
Cosmos Health Introduces the "18 Series" in the United StatesA Science-Driven Nutraceutical Platform Built on Patented Ingredients, Published Clinical Research, and Exact Clinical Dosing; Targeting a Portfolio of 18 Clinically Validated Products - Quantisnow
2.29%
0.00%
大文字化:
|
ボリューム (24 時間):